Taken together, our data indicate that ARIH1 plays a role in promoting anti-tumor immunity, and that ES-072 is a promising agent to boost anti-tumor immunity and anti-CTLA4 immune checkpoint blockade immunotherapies. Here, ARIH1 is linked to neoplasm.